MedTrace Logo

Cognitive Screening in Lung Cancer Patients

NCT06727370 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2024-12-10

No results posted yet for this study

Summary

This study aims to investigate the occurrence of cancer and adjuvant therapy-related cognitive impairment in patients with both NSCLC and SCLC. The primary endpoint measure will be the presence of cognitive impairment during the first year after enrollment through the administration of a comprehensive neuropsychological assessment.

Conditions

Sponsors & Collaborators

  • European Institute of Oncology

    lead OTHER

Principal Investigators

  • Gabriella Pravettoni · Istituto Europeo di Oncologia

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-10
Primary Completion
2025-12-31
Completion
2025-12-31

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06727370 on ClinicalTrials.gov